Vigil Neuroscience (VIGL) Guggenheim Securities Inaugural Healthcare Innovation Conference summary

Company overview and differentiation

• Focuses on microglia-targeted therapeutics for rare and common neurodegenerative diseases, leveraging a precision-based approach to reduce translational risk and accelerate proof of concept.

• Only company with both a fully human monoclonal antibody and a first-in-class small molecule TREM2 agonist, enabling a diversified pipeline.

• Lead antibody asset, Iluzanebart, is in phase II for ALSP, while the small molecule is in phase I for Alzheimer's disease.

• First to generate clinical data supporting TREM2 as a therapeutic target in neurodegeneration.

• Secured a $40 million strategic investment from Sanofi, extending financial runway into 2026.

ALSP clinical development and regulatory strategy

• Phase II open-label study in ALSP includes 20 patients (20mg and 40mg cohorts), with interim six-month data showing slowed disease progression in patients with active disease.

• Natural history study provides critical insights into biomarker and clinical endpoint progression, supporting use of MRI as a sensitive biomarker.

• FDA has indicated openness to accelerated approval based on biomarker data, with a focus on MRI and its correlation with clinical outcomes.

• Full 12-month data from both dose cohorts expected in the first half of next year, with disclosure planned after alignment with the FDA.

• Confirmatory phase III study would need to be underway at the time of filing for accelerated approval.

Biomarker and patient insights

• MRI changes, particularly ventricular and white matter volume, show strong correlation with clinical decline, making MRI a primary biomarker for regulatory discussions.

• Soluble CSF1R and NfL levels are also tracked as disease pathology and severity markers.

• Clinical endpoints like MoCA and CBFS are considered, but are noisier and require longer observation for meaningful separation.

• Patient listening sessions with the FDA highlighted the need for shorter, biomarker-driven studies due to the rapid progression and rarity of ALSP.